Insight Molecular Diagnostics
IMDX
87 hedge funds and large institutions have $282M invested in Insight Molecular Diagnostics in 2021 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 5 closing their positions.
580% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 5
260% more capital invested
Capital invested by funds: $78.4M → $282M (+$204M)
175% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 12
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
90% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $783K
45% more funds holding
Funds holding: 60 → 87 (+27)
0.63% more ownership
Funds ownership: 2.44% → 3.07% (+0.63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$28.2M |
| 2 |
O
OrbiMed
New York
|
+$9.97M |
| 3 |
BC
Broadwood Capital
New York
|
+$9.78M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$7.1M |
| 5 |
BlackRock
New York
|
+$6.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$596K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$505K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$261K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$164K |
| 5 |
VF
Virtu Financial
New York
|
-$89K |
IMDX Hedge Fund Activity: Q1 2021 in Review
87 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2021, worth a combined $282M — up 260% from $78.4M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IMDX positions and 5 closed out — a net gain of 29 holders — while 33 added to existing stakes and 12 trimmed.
The largest buyer was Pura Vida Investments, adding an estimated $28.2M. The largest seller was GSA Capital Partners, cutting an estimated $596K.
- 87 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2021, up from 60 in Q4 2020.
- Funds reported $282M of Insight Molecular Diagnostics stock for Q1 2021, up 260% quarter-over-quarter.
- 34 funds opened new Insight Molecular Diagnostics positions in Q1 2021 and 5 closed out, a net change of +29 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2021 was Pura Vida Investments, an estimated $28.2M added.
- The largest Insight Molecular Diagnostics seller in Q1 2021 was GSA Capital Partners, an estimated $596K sold.
Based on aggregated 13F filings for Q1 2021.